235 related articles for article (PubMed ID: 9862428)
21. Aggregation and neurotoxicity of alpha-synuclein and related peptides.
el-Agnaf OM; Irvine GB
Biochem Soc Trans; 2002 Aug; 30(4):559-65. PubMed ID: 12196137
[TBL] [Abstract][Full Text] [Related]
22. Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
Kahle PJ; Neumann M; Ozmen L; Haass C
Ann N Y Acad Sci; 2000; 920():33-41. PubMed ID: 11193173
[TBL] [Abstract][Full Text] [Related]
23. The effects of aggregation-inducing motifs on amyloid formation of model proteins related to neurodegenerative diseases.
Tanaka M; Machida Y; Nishikawa Y; Akagi T; Morishima I; Hashikawa T; Fujisawa T; Nukina N
Biochemistry; 2002 Aug; 41(32):10277-86. PubMed ID: 12162743
[TBL] [Abstract][Full Text] [Related]
24. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
Li J; Uversky VN; Fink AL
Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
[TBL] [Abstract][Full Text] [Related]
25. Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma.
El-Agnaf OM; Salem SA; Paleologou KE; Cooper LJ; Fullwood NJ; Gibson MJ; Curran MD; Court JA; Mann DM; Ikeda S; Cookson MR; Hardy J; Allsop D
FASEB J; 2003 Oct; 17(13):1945-7. PubMed ID: 14519670
[TBL] [Abstract][Full Text] [Related]
26. Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells.
Hasegawa T; Matsuzaki M; Takeda A; Kikuchi A; Akita H; Perry G; Smith MA; Itoyama Y
Brain Res; 2004 Jul; 1013(1):51-9. PubMed ID: 15196967
[TBL] [Abstract][Full Text] [Related]
27. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson's disease-associated mutations.
Kawamata H; McLean PJ; Sharma N; Hyman BT
J Neurochem; 2001 May; 77(3):929-34. PubMed ID: 11331421
[TBL] [Abstract][Full Text] [Related]
28. Fe(II)-induced DNA damage in alpha-synuclein-transfected human dopaminergic BE(2)-M17 neuroblastoma cells: detection by the Comet assay.
Martin FL; Williamson SJ; Paleologou KE; Hewitt R; El-Agnaf OM; Allsop D
J Neurochem; 2003 Nov; 87(3):620-30. PubMed ID: 14535945
[TBL] [Abstract][Full Text] [Related]
29. Phthalocyanine tetrasulfonates affect the amyloid formation and cytotoxicity of alpha-synuclein.
Lee EN; Cho HJ; Lee CH; Lee D; Chung KC; Paik SR
Biochemistry; 2004 Mar; 43(12):3704-15. PubMed ID: 15035641
[TBL] [Abstract][Full Text] [Related]
30. Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.
Chorfa A; Bétemps D; Morignat E; Lazizzera C; Hogeveen K; Andrieu T; Baron T
Toxicol Sci; 2013 Jun; 133(2):289-97. PubMed ID: 23535362
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
Zhou W; Hurlbert MS; Schaack J; Prasad KN; Freed CR
Brain Res; 2000 Jun; 866(1-2):33-43. PubMed ID: 10825478
[TBL] [Abstract][Full Text] [Related]
32. Neurodegenerative disease: amyloid pores from pathogenic mutations.
Lashuel HA; Hartley D; Petre BM; Walz T; Lansbury PT
Nature; 2002 Jul; 418(6895):291. PubMed ID: 12124613
[TBL] [Abstract][Full Text] [Related]
33. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
Li W; West N; Colla E; Pletnikova O; Troncoso JC; Marsh L; Dawson TM; Jäkälä P; Hartmann T; Price DL; Lee MK
Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2162-7. PubMed ID: 15684072
[TBL] [Abstract][Full Text] [Related]
34. Review: formation and properties of amyloid-like fibrils derived from alpha-synuclein and related proteins.
El-Agnaf OM; Irvine GB
J Struct Biol; 2000 Jun; 130(2-3):300-9. PubMed ID: 10940234
[TBL] [Abstract][Full Text] [Related]
35. alpha-Synuclein membrane interactions and lipid specificity.
Jo E; McLaurin J; Yip CM; St George-Hyslop P; Fraser PE
J Biol Chem; 2000 Nov; 275(44):34328-34. PubMed ID: 10915790
[TBL] [Abstract][Full Text] [Related]
36. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
Li W; Lesuisse C; Xu Y; Troncoso JC; Price DL; Lee MK
J Neurosci; 2004 Aug; 24(33):7400-9. PubMed ID: 15317865
[TBL] [Abstract][Full Text] [Related]
37. Beta-Synuclein-derived peptides with neuroprotective activity: an alternative treatment of neurodegenerative disorders?
Windisch M; Hutter-Paier B; Schreiner E; Wronski R
J Mol Neurosci; 2004; 24(1):155-65. PubMed ID: 15314265
[TBL] [Abstract][Full Text] [Related]
38. Oligopeptide-mediated acceleration of amyloid fibril formation of amyloid beta(Abeta) and alpha-synuclein fragment peptide (NAC).
Kuroda Y; Maeda Y; Hanaoka H; Miyamoto K; Nakagawa T
J Pept Sci; 2004 Jan; 10(1):8-17. PubMed ID: 14959887
[TBL] [Abstract][Full Text] [Related]
39. alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease.
Lo Bianco C; Ridet JL; Schneider BL; Deglon N; Aebischer P
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10813-8. PubMed ID: 12122208
[TBL] [Abstract][Full Text] [Related]
40. Interaction of the molecular chaperone alphaB-crystallin with alpha-synuclein: effects on amyloid fibril formation and chaperone activity.
Rekas A; Adda CG; Andrew Aquilina J; Barnham KJ; Sunde M; Galatis D; Williamson NA; Masters CL; Anders RF; Robinson CV; Cappai R; Carver JA
J Mol Biol; 2004 Jul; 340(5):1167-83. PubMed ID: 15236975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
